• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

Isorhamnetin 3-O-galactoside

CAS No. 6743-92-6

Isorhamnetin 3-O-galactoside ( —— )

产品货号. M31756 CAS No. 6743-92-6

Isorhamnetin 3-O-galactoside shows antioxidant, anti-inflammatory, neuroprotective,and barrier protective activities, it could be used as a candidate therapeutic for treatment of severe vascular inflammatory diseases.

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
10MG ¥2160 有现货
50MG 获取报价 有现货
100MG 获取报价 有现货
10MG ¥2160 有现货
50MG 获取报价 有现货
100MG 获取报价 有现货

生物学信息

  • 产品名称
    Isorhamnetin 3-O-galactoside
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    Isorhamnetin 3-O-galactoside shows antioxidant, anti-inflammatory, neuroprotective,and barrier protective activities, it could be used as a candidate therapeutic for treatment of severe vascular inflammatory diseases.
  • 产品描述
    Isorhamnetin 3-O-galactoside shows antioxidant, anti-inflammatory, neuroprotective,and barrier protective activities, it could be used as a candidate therapeutic for treatment of severe vascular inflammatory diseases.
  • 同义词
    ——
  • 通路
    Others
  • 靶点
    Other Targets
  • 受体
    ——
  • 研究领域
    ——
  • 适应症
    ——

化学信息

  • CAS Number
    6743-92-6
  • 分子量
    478.4
  • 分子式
    C22H22O12
  • 纯度
    >98% (HPLC)
  • 溶解度
    ——
  • SMILES
    ——
  • 化学全称
    ——

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

产品手册
关联产品
  • QS-21

    QS-21, an immunostimulatory saponin, is a powerful vaccine adjuvant that stimulates both Th2 humoral and Th1 cell-mediated immune responses by interacting with antigen presenting cells (APCs) and T cells.

  • Methyl nomilinate

    Methyl nomilinate from citrus can modulate cell cycle regulators to induce cytotoxicity in human colon cancer (SW480) cells in vitro.

  • Etelcalcetide

    Etelcalcetide (AMG 416) is a synthetic peptide as an activator of the calcium sensing receptor (CaSR). Etelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis.